Abstract
Human amniotic fluid cells have been used traditionally as a diagnostic tool for genetic anomalies. More recently it has been recognized that amniotic fluid contains populations of stem cells. Mesenchymal stem cells (AFMSC) were first to be described. These cells are able to differentiate towards mesodermal lineages. More recently cells with broader potential, defined as amniotic fluid stem cells (AFSC), were also isolated. They have intermediate characteristics between embryonic and adult stem cells and are able to differentiate into lineages representative of all three germ layers but unlike ES cells they do not form tumours in vivo. Furthermore, AFSC have been reverted to functional pluripotency in a transgene-free approach using an epigenetics modifier. These characteristics, together with absence of ethical issues concerning their employment, have made stem cells from amniotic fluid a promising candidate for cell therapy and tissue engineering.
Keywords: Amniotic fluid, amniotic fluid mesenchymal stem cells, amniotic fluid stem cells, cell therapy, differentiation, pluripotency, tissue engineering, epigenetics modifier, transgene-free approach, ECTODERM
Current Stem Cell Research & Therapy
Title:Therapeutic Potential of Amniotic Fluid Stem Cells
Volume: 8 Issue: 2
Author(s): Hassan Abdulrazzak, Paolo De Coppi and Pascale V Guillot
Affiliation:
Keywords: Amniotic fluid, amniotic fluid mesenchymal stem cells, amniotic fluid stem cells, cell therapy, differentiation, pluripotency, tissue engineering, epigenetics modifier, transgene-free approach, ECTODERM
Abstract: Human amniotic fluid cells have been used traditionally as a diagnostic tool for genetic anomalies. More recently it has been recognized that amniotic fluid contains populations of stem cells. Mesenchymal stem cells (AFMSC) were first to be described. These cells are able to differentiate towards mesodermal lineages. More recently cells with broader potential, defined as amniotic fluid stem cells (AFSC), were also isolated. They have intermediate characteristics between embryonic and adult stem cells and are able to differentiate into lineages representative of all three germ layers but unlike ES cells they do not form tumours in vivo. Furthermore, AFSC have been reverted to functional pluripotency in a transgene-free approach using an epigenetics modifier. These characteristics, together with absence of ethical issues concerning their employment, have made stem cells from amniotic fluid a promising candidate for cell therapy and tissue engineering.
Export Options
About this article
Cite this article as:
Abdulrazzak Hassan, De Coppi Paolo and V Guillot Pascale, Therapeutic Potential of Amniotic Fluid Stem Cells, Current Stem Cell Research & Therapy 2013; 8 (2) . https://dx.doi.org/10.2174/1574888X11308020002
DOI https://dx.doi.org/10.2174/1574888X11308020002 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vaccines for Cytomegalovirus
Infectious Disorders - Drug Targets Roles of miRNA in Cardiovascular Development and Dysfunction
Current Medicinal Chemistry Mid-Aortic Syndrome: A Rare Cause of Renovascular Hypertension in Childhood Treated Percutaneously with an Unusual Vascular Access
Current Pediatric Reviews Molecular Effects of the CTG Repeats in Mutant Dystrophia Myotonica Protein Kinase Gene
Current Genomics Time Space Translation: A Hox Mechanism for Vertebrate A-P Patterning
Current Genomics MicroRNAs in Aortic Disease
Current Topics in Medicinal Chemistry Contextualizing the Genes Altered in Bladder Neoplasms in Pediatric and Teen Patients Allows Identifying Two Main Classes of Biological Processes Involved and New Potential Therapeutic Targets
Current Genomics The Roles of Antimicrobial Peptides in Innate Host Defense
Current Pharmaceutical Design Pharmacologically Targeting the Primary Defect and Downstream Pathology in Duchenne Muscular Dystrophy
Current Gene Therapy Current Therapeutic Concepts in Peripartum Cardiomyopathy
Current Pharmaceutical Design Molecular Basis of Antiretroviral Drugs-Associated Long-Term Toxicity: How Bad can Good Drugs Be?
Current Medicinal Chemistry - Anti-Infective Agents Muscarinic Acetylcholine Receptor-Interacting Proteins (mAChRIPs): Targeting the Receptorsome
Current Drug Targets Endocarditis Due to Salmonella Enterica Subsp. Arizonae in a Patient with Sickle Cell Disease: A Case Report and Review of the Literature
Cardiovascular & Hematological Disorders-Drug Targets Genetically Modified Endothelial Progenitor Cells in the Therapy of Cardiovascular Disease and Pulmonary Hypertension
Current Vascular Pharmacology Antibody Penetration Into Living Cells: Pathogenic, Preventive and Immuno-Therapeutic Implications
Current Pharmaceutical Design Policy and Health Implications of Using the U.S. Food and Drug Administration Product Design Approach in Reducing Tobacco Product Risk
Current Drug Abuse Reviews PDE5 Inhibitor Treatment Options for Urologic and Non-Urologic Indications: 2012 Update
Current Pharmaceutical Design RNA Splicing Manipulation: Strategies to Modify Gene Expression for a Variety of Therapeutic Outcomes
Current Gene Therapy A Practical Approach to Diagnosis and Treatment of Symptomatic Thromboembolic Events in Children with Acute Lymphoblastic Leukemia: Recommendations of the “Coagulation Defects” AIEOP Working Group
Recent Patents on Cardiovascular Drug Discovery Mitochondrial Dysfunction and Oxidative Stress in Insulin Resistance
Current Pharmaceutical Design